This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R DTC. This is a non-interventional study using secondary data derived from a real-world Electronic Health Record (rEHR) database in China.
Study Type
OBSERVATIONAL
Enrollment
200
Proportion of Patients Receiving Second-line Systematic Therapy
Second-line systematic therapy includes lenvatinib, anlotinib, sorafenib, donafenib, and D+T.
Time frame: Up to 6 years
Duration of Second-line Systematic Therapy
Duration of therapy with lenvatinib, anlotinib, sorafenib, donafenib, and D+T.
Time frame: Up to 6 years
Proportion of Patients by Demographics and Clinical Characteristics
Demographics and clinical characteristics include sex/gender, Tumor Node Metastasis (TNM) stage, BRAF V600E and co-mutation status, presence of distant metastasis, and MKI tolerability-related comorbidities.
Time frame: Baseline
Age
Time frame: Baseline
Proportion of Patients Who had Surgery Prior to Second-line Systematic Therapy
Time frame: Baseline
Proportion of Patients Who Received 131I Radioiodine Therapy Prior to Second-line Systematic Therapy
Time frame: Baseline
Proportion of Patients by First-line Therapy
Proportion of patients who received first-line lenvatinib, anlotinib, sorafenib, donafenib, and D+T.
Time frame: Baseline
Duration Between First Diagnosis of DTC and Treatment Initiation
Time frame: Baseline
Proportion of Patients by Timing and Method of BRAF Testing
Novartis Pharmaceuticals
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Timing categories include at initial diagnosis, at recurrence or metastasis, prior to second-line initiation, and other/unknown.
Time frame: Baseline, up to 6 years